Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437993 | 1.00 | HTR1A (0.31) | HTR1AHTR7HTR2BTMEM97SIGMAR1 | |
| SCHEMBL15303180 | 0.94 | — | — | |
| SCHEMBL16193623 | 0.92 | — | — | |
| SCHEMBL30148542 | 0.84 | — | — | |
| SCHEMBL9901210 | 0.84 | — | — | |
| SCHEMBL15306190 | 0.83 | — | — | |
| SCHEMBL9901499 | 0.78 | — | — | |
| SCHEMBL17188995 | 0.78 | HTR1A (0.31) | HTR1AHTR7HTR2BTMEM97SIGMAR1 | |
| SCHEMBL9901103 | 0.75 | — | — | |
| SCHEMBL29438014 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390394-B1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | disclosed |
| US-9833452-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9833452-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170273981-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2017-09-28 | — | — | US | disclosed |
| WO-2017103604-A1 | HYDANTOIN MODULATORS OF KV3 CHANNELS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | disclosed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | disclosed |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-09-01 | — | — | US | disclosed |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-09-01 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20150336936-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2015-11-26 | — | — | US | disclosed |
| US-20150336936-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2015-11-26 | — | — | US | disclosed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | disclosed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | disclosed |
| EP-2649066-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336936-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | HTR1A 1279/4885HTR7 1973/4885HTR2B 1039/4885 |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | HTR1A 670/4885HTR7 898/4885HTR2B 879/4885 |
| US-20170273981-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | HTR1A 670/4885HTR7 898/4885HTR2B 879/4885 |
| US-20160317537-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | HTR1A 1279/4885HTR7 1973/4885HTR2B 1039/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | HTR1A 670/4885HTR7 898/4885HTR2B 879/4885 |
| US-20140323508-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | HTR1A 631/4885HTR7 1557/4885HTR2B 646/4885 |
| US-20180036308-A1 | NOVEL COMPOUNDS | CYFIP1, CYFIP2, ZFX | HTR1A 3017/4885HTR7 3536/4885HTR2B 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.